key: cord-1034788-60qaxmzp authors: Hirotsu, Yosuke; Maejima, Makoto; Shibusawa, Masahiro; Amemiya, Kenji; Nagakubo, Yuki; Hosaka, Kazuhiro; Sueki, Hitomi; Hayakawa, Miyoko; Mochizuki, Hitoshi; Tsutsui, Toshiharu; Kakizaki, Yumiko; Miyashita, Yoshihiro; Omata, Masao title: Analysis of a persistent viral shedding patient infected with SARS-CoV-2 by RT-qPCR, FilmArray Respiratory Panel v2.1, and antigen detection date: 2020-10-29 journal: J Infect Chemother DOI: 10.1016/j.jiac.2020.10.026 sha: 0db9c670347e96561d48f2ff95568c35d6ab82fa doc_id: 1034788 cord_uid: 60qaxmzp Various diagnostic tests utilizing different principles are currently under development for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, these tests can occasionally produce discrepant results, causing confusion in their interpretation. Here, we evaluated the performance and features of three diagnostic assays: quantitative reverse transcription polymerase chain reaction (RT-qPCR), FilmArray Respiratory Panel (RP) v2.1, and the LUMIPULSE antigen test. Twenty-seven serial nasopharyngeal swabs were collected from a prolonged viral shedding patient who had been hospitalized for 51 days. We examined the SARS-CoV-2 detection rates of the three tests. The overall agreement rate was 81% between RT-qPCR and FilmArray RP v2.1, 63% between the antigen test and FilmArray RP v2.1, and 59% between the antigen test and RT-qPCR. We obtained concordant results in samples with high viral loads (low threshold cycle values) by all three tests. RT-qPCR and FilmArray RP v2.1 accurately detected SARS-CoV-2 at the early to intermediate phases of infection, but the results varied at the late phase. The antigen test also produced a positive result at the early phase but varied at the intermediate phase and consistently produced negative results at late phase of infection. These results demonstrated FilmArray RP v2.1 could detect SARS-CoV-2 with accuracy comparable to RT-qPCR. Further, there were discrepant results using different types of diagnostic tests during the clinical course of prolonged viral shedding patient. We provided insights into how to utilize different types of kits to assess and manage SARS-CoV-2 infections. While RT-qPCR remains the gold standard method and is widely conducted for detecting SARS-CoV-2, many laboratories are using diagnostic tests utilizing different principles. As these tests have unique nucleic acid sequence and antigen/epitope targets, they also differ in sensitivity and specificity. Such variability between diagnostic tests could cause confusion amongst clinicians and healthcare workers as to the appropriate test to select and the interpretation of results. A 86-year-old woman with a medical history of chronic atrial fibrillation was transferred to the other hospital due to subdural hematoma. She had fever (37.6 °C), cough and poor oxygenation (SpO2: 90%). SARS-CoV-2 was detected in nasopharyngeal swabs by RT-qPCR and the diagnosis of COVID-19 infection was made. Computed tomography of the chest showed pneumonia with diffuse glass shadow in the bilateral lung fields. The infected patient with moderate symptom was transferred to our hospital and treated with camostat mesilate. Duration of hospitalization was 51 days. We collected 27 serial nasopharyngeal swabs from the patient with persistent viral shedding during hospitalization. We analyzed these swab samples using quantitative reverse transcription PCR (RT-qPCR), FilmArray RP v2.1 (BioMérieux, Marcy-l'Etoile, France), and the LUMIPULSE antigen test (Fujirebio, Tokyo, Japan) to evaluate the performance of these assays at detecting SARS-CoV-2. Total nucleic acid was automatically isolated from viral transport media [3, 4] , and subjected to RT-qPCR with the primers and probe targeting the SARS-CoV-2 nucleocapsid gene [5, 6] . Threshold cycle (Ct) values were assigned to each PCR reaction, and the J o u r n a l P r e -p r o o f amplification curve was visually assessed. We also conducted multiplex PCR targeting using FilmArray RP v2.1 [7] . FilmArray RP v2.1 includes two primer sets targeting SARS-CoV-2 membrane and spike genes. The antigen level was determined with Detection rates of SARS-CoV-2 were 70% (19/27), 67% (18/27), and 30% (8/27) by RT-qPCR, FilmArray RP v2.1, and the antigen test, respectively. These results suggest that nucleic acid amplification has higher sensitivity than antigen detection. FilmArray RP v2.1 did not detect other viruses or bacteria in the samples, indicating that this patient was not co-infected with other pathogens. and FilmArray RP showed "positive to negative" or "negative to positive" fluctuations (Table 1 ), as we previously described [8] . The antigen test consistently returned negative results at the late phase of infection (Table 1) . RT-qPCR can quantitatively evaluate viral RNA levels with high sensitivity. Our results show that both RT-qPCR and Film Array RP v2.1 can detect prolonged viral J o u r n a l P r e -p r o o f shedding [9] [10] [11] . Half of COVID-19 patients shed virus particles up to 25 days after the first positive PCR test [12] . Higher viral loads (lower Ct values) were observed in COVID-19 patients in the first week of the onset of symptoms and viable SARS-CoV-2 was cultured within 7-9 days of onset [9, 11] . However, infectious SARS-CoV-2 are not always present in patients who have prolonged viral production and shedding [13, 14] . As RT-qPCR and Film Array RP v2.1 cannot distinguish between RNA of live viruses from that of non-infectious viruses, we should carefully interpret Ct values and viral load results, especially in the late phase of the infection period. We also consider that the contamination of PCR inhibitor reduces amplification efficiency, which may cause negative results in sample with low viral RNA. In summary, the accuracy was comparable between RT-qPCR and FilmArray RP v2.1. Using different types of test kits, we encountered discrepancies between the results from a prolonged viral shedding patient depending on the viral load and stage of infection. Although further studies are needed to clarify these results are observed in other patients, our results provide the strong and weak points of each test (Table 2 ). These features may help healthcare worker to properly interpret results. Combining diagnostic tests could provide accurate results and be beneficial to better manage COVID-19 infected patients. MM, MS, KA, YN, KH, and HS contributed to sample preparation and data collection, data analysis. MH and HM contributed to supervision. TT, YK and YM contributed to provide resources. MO contributed to supervision and writing -review & editing. The Institutional Review Board at Yamanashi Central Hospital, Japan, approved this study (Approval No. C2019-30 and C2020-9). Written informed consent was obtained from the patient to publish this case. Clinical evaluation of the BioFire® Respiratory Panel 2.1 and detection of SARS-CoV-2 Pooling RT-PCR test of SARS-CoV-2 for large cohort of 'healthy' and infection-suspected patients: A prospective and consecutive study on 1,000 individuals Environmental cleaning is effective for the eradication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in contaminated hospital rooms: A patient from the Diamond Princess cruise ship Double-quencher probes improve detection sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a reverse-transcription polymerase chain reaction (RT-PCR) assay Development of Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan Analysis of Covid-19 and non-Covid-19 viruses, including influenza viruses, to determine the Quantitative RT-PCR using 313 Nasopharyngeal Swabs Including from 7 Serially Followed Patients Temporal dynamics in viral shedding and transmissibility of COVID-19 Positive RT-PCR Test Results in Patients Recovered From COVID-19 Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States Prolonged shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) RNA among patients with coronavirus disease 2019 (COVID-19) SARS-CoV-2 shedding and infectivity SARS-CoV-2: The viral shedding vs infectivity dilemma We thank Shintaro Yagi, Satoshi Kojima, Hisashi Nojima, Masayasu Imaizumi, Yukie Ohtakagi, and Eri Inagaki (Fujirebio Inc.) for technical assistance and all of the medical and ancillary hospital staff and the patients for consenting to participate.